Our data indicated that overexpression of ALCAM predicted poor outcomes for clinical features like nodal status (positive vs. negative), tumor stage (T3, T4 vs. T1, T2), distant metastasis (M1 vs. M0), grade (grade3 vs. grade1,2) and age (> 60 vs. < 60). This evidence concerns the gene ALCAM and neoplasm.